These changes may indirectly trigger involuntary diaphragmatic contractions in some patients, especially during dose adjustments or when combined with dietary changes
[5] [2] Patients starting GLP-1 therapy should be aware of: Potential mood changes during the adjustment period, particularly if experiencing significant gastrointestinal side effects The importance of continuing existing mental health treatments unless advised otherwise by their healthcare team Realistic expectations regarding weight loss and metabolic improvements, as unrealistic goals can lead to disappointment Healthcare professionals prescribing GLP-1 agonists should: Screen for depression and anxiety at baseline and during follow-up appointments Monitor for mood changes , particularly in patients with pre-existing mental health conditions Ensure coordinated care between diabetes/obesity services and mental health teams when appropriate It is essential to recognise that GLP-1 agonists are not a substitute for evidence-based depression treatments, including psychological therapies and antidepressant medications when indicated
This article explores the science behind persistent sugar cravings during GLP-1 treatment and provides evidence-based strategies for managing them effectively
L-Carnitine and Heart Health Cardiovascular diseases are a leading cause of mortality worldwide, and managing risk factors such as high blood pressure, cholesterol, and oxidative stress is vital
The goal is sustainable metabolic support
You need the greater potency and longer treatment duration of a GLP-1 medication
,aspect=ignore)
